CNBC Pro

An effective vaccine could be the turning point for value stocks, but perhaps not just yet

Share
Traders work the floor of the New York Stock Exchange.
NYSE

Value stocks have been on a tear in the last week after positive vaccine news from Pfizer and BioNTech raised hope of the U.S. economy staging a fast recovery next year. However, investors loading up on beaten-down value names should brace for some volatile swings as risks to the group linger.

The iShares Russell 1000 Value ETF (IWD) rallied 5.7% last week after Pfizer and BioNTech said Monday that their coronavirus vaccine candidate was more than 90% effective at preventing the coronavirus during a late-stage trial. Value's gain came at the expense of high-flying growth stocks. The iShares Russell 1000 Growth ETF (IWF) lost 1.2% last week.

More In Investing trends

CNBC ProMorgan Stanley says stocks shouldn't be rebounding, but retail investors keep buying
CNBC ProFrom clean energy to health, Morgan Stanley picks India stocks set to see strong growth
CNBC ProBank of America reveals its top stocks for exposure to multi-trillion dollar future trends